Will Pharma End Up Paying For The Infrastructure Bill?
Or can industry thread the donut hole and prevent government price negotiations from becoming a part of the legislative tsunami?
You may also be interested in...
A policy eliminating rebates in the Medicare Part D program will be delayed until Jan. 1, 2026 – and is very likely to be repealed altogether. If that staves off more draconian reforms, the biopharma industry will celebrate.
White House confirms that it will not be pushing major drug pricing provisions to help pay for its next multi-trillion dollar legislative proposal. That sounds like good news for industry – but don’t pop the champagne just yet.
US Drug Pricing Bill’s Prospects Will Be Shaped By Whether Public Worries More About Access Than Cost
HR 3 has been re-introduced, and some provisions may be attached to the White House’s infrastructure bill, but the government price negotiation system envisioned by the bill may fail – if industry can convince Congress to focus on access to medicines, not their cost.